Top

Published in:

Open Access 01-12-2022 | Research

Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant African swine fever virus proteins fused with bacterial lipoprotein OprI

Published in: Virology Journal | Issue 1/2022

Abstract

Background

African swine fever (ASF) is a highly fatal swine disease, which threatens the global pig industry. There is no commercially available vaccine against ASF and effective subunit vaccines would represent a real breakthrough.

Methods

In this study, we expressed and purified two recombinant fusion proteins, OPM (OprI-p30-modified p54) and OPMT (OprI-p30-modified p54-T cell epitope), which combine the bacterial lipoprotein OprI with ASF virus proteins p30 and p54. Purified recombinant p30 and modified p54 expressed alone or fused served as controls. The activation of dendritic cells (DCs) by these proteins was first assessed. Then, humoral and cellular immunity induced by the proteins were evaluated in mice.

Results

Both OPM and OPMT activated DCs with elevated expression of relevant surface molecules and proinflammatory cytokines. Furthermore, OPMT elicited the highest levels of antigen-specific IgG responses, cytokines including interleukin-2, interferon-γ, and tumor necrosis factor-α, and proliferation of lymphocytes. Importantly, the sera from mice vaccinated with OPM or OPMT neutralized more than 86% of ASF virus in vitro.

Conclusions

Our results suggest that OPMT has good immunostimulatory activities and immunogenicity in mice, and might be an appropriate candidate to elicit immune responses in swine. Our study provides valuable information on further development of a subunit vaccine against ASF.

Blome S, Franzke K, Beer M. African swine fever - A review of current knowledge. Virus Res. 2020;287:198099.PubMed

Galindo I, Alonso C. African swine fever virus: a review. Viruses. 2017;9:103.PubMedCentral

Sánchez-Cordón PJ, Montoya M, Reis AL, Dixon LK. African swine fever: a re-emerging viral disease threatening the global pig industry. Vet J. 2018;233:41–8.PubMedPubMedCentral

Revilla Y, Pérez-Núñez D, Richt JA. African swine fever virus biology and vaccine approaches. Adv Virus Res. 2018;100:41–74.PubMed

Alonso C, Borca M, Dixon L, Revilla Y, Rodriguez F, Escribano JM, Ictv Report C. ICTV virus taxonomy profile: asfarviridae. J Gen Virol. 2018;99:613–4.PubMed

Karger A, Pérez-Núñez D, Urquiza J, Hinojar P, Alonso C, Freitas FB, Revilla Y, Le Potier MF, Montoya M. An update on african swine fever virology. Viruses. 2019;11:864.PubMedCentral

Quembo CJ, Jori F, Vosloo W, Heath L. Genetic characterization of African swine fever virus isolates from soft ticks at the wildlife/domestic interface in Mozambique and identification of a novel genotype. Transbound Emerg Dis. 2018;65:420–31.PubMed

Gallardo MC, Reoyo AT, Fernández-Pinero J, Iglesias I, Muñoz MJ, Arias ML. African swine fever: a global view of the current challenge. Porcine Health Manag. 2015;1:21.PubMedPubMedCentral

Ge S, Li J, Fan X, Liu F, Li L, Wang Q, Ren W, Bao J, Liu C, Wang H, et al. Molecular characterization of African swine fever virus, China, 2018. Emerg Infect Dis. 2018;24:2131–3.PubMedPubMedCentral

10.

Kim HJ, Cho KH, Lee SK, Kim DY, Nah JJ, Kim HJ, Kim HJ, Hwang JY, Sohn HJ, Choi JG, et al. Outbreak of African swine fever in South Korea, 2019. Transbound Emerg Dis. 2020;67:473–5.PubMed

11.

Arias M, de la Torre A, Dixon L, Gallardo C, Jori F, Laddomada A, Martins C, Parkhouse RM, Revilla Y, Rodriguez FAJ. Approaches and perspectives for development of african swine fever virus vaccines. Vaccines (Basel). 2017;5:35.

12.

Rock DL. Thoughts on African swine fever vaccines. Viruses. 2021;13:943.PubMedPubMedCentral

13.

Sánchez EG, Pérez-Núñez D, Revilla Y. Development of vaccines against African swine fever virus. Virus Res. 2019;265:150–5.PubMed

14.

Mebus CA. African swine fever. Adv Virus Res. 1988;35:251–69.PubMed

15.

Blome S, Gabriel C, Beer M. Modern adjuvants do not enhance the efficacy of an inactivated African swine fever virus vaccine preparation. Vaccine. 2014;32:3879–82.PubMed

16.

Mebus CA, Dardiri AH. Western hemisphere isolates of African swine fever virus: asymptomatic carriers and resistance to challenge inoculation. Am J Vet Res. 1980;41:1867–9.PubMed

17.

O’Donnell V, Holinka LG, Sanford B, Krug PW, Carlson J, Pacheco JM, Reese B, Risatti GR, Gladue DP, Borca MV. African swine fever virus Georgia isolate harboring deletions of 9GL and MGF360/505 genes is highly attenuated in swine but does not confer protection against parental virus challenge. Virus Res. 2016;221:8–14.PubMed

18.

Borca MV, Ramirez-Medina E, Silva E, Vuono E, Rai A, Pruitt S, Holinka LG, Velazquez-Salinas L, Zhu J, Gladue DP. Development of a highly effective African swine fever virus vaccine by deletion of the I177L gene results in sterile immunity against the current epidemic eurasia strain. J Virol. 2020. https://doi.org/10.1128/JVI.02017-19.CrossRefPubMedPubMedCentral

19.

Muñoz-Pérez C, Jurado C, Sánchez-Vizcaíno JM. African swine fever vaccine: turning a dream into reality. Transbound Emerg Dis. 2021;68:2657–68.PubMed

20.

Borca MV, Ramirez-Medina E, Silva E, Vuono E, Rai A, Pruitt S, Espinoza N, Velazquez-Salinas L, Gay CG, Gladue DP. ASFV-G-∆I177L as an effective oral nasal vaccine against the eurasia strain of Africa swine fever. Viruses. 2021;13:765.PubMedPubMedCentral

21.

Tran XH, Le TTP, Nguyen QH, Do TT, Nguyen VD, Gay CG, Borca MV, Gladue DP. African swine fever virus vaccine candidate ASFV-G-ΔI177L efficiently protects European and native pig breeds against circulating Vietnamese field strain. Transbound Emerg Dis. 2021. https://doi.org/10.1111/tbed.14329.CrossRefPubMed

22.

Zhang Y, Ke J, Zhang J, Yang J, Yue H, Zhou X, Qi Y, Zhu R, Miao F, Li Q, et al. African swine fever virus bearing an I226R gene deletion elicits robust immunity in pigs to African swine fever. J Virol. 2021;95:e0119921.PubMed

23.

Velazquez-Salinas L, Ramirez-Medina E, Rai A, Pruitt S, Vuono EA, Espinoza N, Gladue DP, Borca MV. Development real-time PCR assays to genetically differentiate vaccinated pigs from infected pigs with the eurasian strain of African swine fever virus. Front Vet Sci. 2021;8:768869.PubMedPubMedCentral

24.

Dixon LK, Sun H, Roberts H. African swine fever. Antiviral Res. 2019;165:34–41.PubMed

25.

Kollnberger SD, Gutierrez-Castaneda B, Foster-Cuevas M, Corteyn A, Parkhouse RME. Identification of the principal serological immunodeterminants of African swine fever virus by screening a virus cDNA library with antibody. J Gen Virol. 2002;83:1331–42.PubMed

26.

Gómez-Puertas P, Rodríguez F, Oviedo JM, Ramiro-Ibáñez F, Ruiz-Gonzalvo F, Alonso C, Escribano JM. Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. J Virol. 1996;70:5689–94.PubMedPubMedCentral

27.

Barderas MG, Rodríguez F, Gómez-Puertas P, Avilés M, Beitia F, Alonso C, Escribano JM. Antigenic and immunogenic properties of a chimera of two immunodominant African swine fever virus proteins. Arch Virol. 2001;146:1681–91.PubMed

28.

Gómez-Puertas P, Rodríguez F, Oviedo JM, Brun A, Alonso C, Escribano JM. The African swine fever virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response. Virology. 1998;243:461–71.PubMed

29.

Argilaguet JM, Pérez-Martín E, Nofrarías M, Gallardo C, Accensi F, Lacasta A, Mora M, Ballester M, Galindo-Cardiel I, López-Soria S, et al. DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies. PLoS ONE. 2012;7:e40942.PubMedPubMedCentral

30.

Lacasta A, Ballester M, Monteagudo PL, Rodríguez JM, Salas ML, Accensi F, Pina-Pedrero S, Bensaid A, Argilaguet J, López-Soria S. Expression library immunization can confer protection against lethal challenge with African swine fever virus. J Virol. 2014;88:13322–32.PubMedPubMedCentral

31.

Basto AP, Piedade J, Ramalho R, Alves S, Soares H, Cornelis P, Martins C, Leitão A. A new cloning system based on the OprI lipoprotein for the production of recombinant bacterial cell wall-derived immunogenic formulations. J Biotechnol. 2012;157:50–63.PubMed

32.

Leitão A, Malur A, Cornelis P, Martins CLV. Identification of a 25-aminoacid sequence from the major African swine fever virus structural protein VP72 recognised by porcine cytotoxic T lymphocytes using a lipoprotein based expression system. J Virol Methods. 1998;75:113–9.PubMed

33.

Cote-Sierra J, Bredan A, Toldos CM, Stijlemans B, Brys L, Cornelis P, Segovia M, de Baetselier P, Revets H. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun. 2002;70:240–8.PubMedPubMedCentral

34.

Leng CH, Chen HW, Chang LS, Liu HH, Liu HY, Sher YP, Chang YW, Lien SP, Huang TY, Chen MY, et al. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol. 2010;47:2015–21.PubMed

35.

Aguado-Martinez A, Basto AP, Mueller J, Balmer V, Manser V, Leitao A, Hemphill A. N-terminal fusion of a toll-like receptor 2-ligand to a Neospora caninum chimeric antigen efficiently modifies the properties of the specific immune response. Parasitology. 2016;143:606–16.PubMed

36.

Aguado-Martínez A, Basto AP, Tanaka S, Ryser LT, Nunes TP, Ortega-Mora L-M, Arranz-Solís D, Leitão A, Hemphill A. Immunization with a cocktail of antigens fused with OprI reduces Neospora caninum vertical transmission and postnatal mortality in mice. Vaccine. 2019;37:473–83.PubMed

37.

Carrascosa AL, Santarén JF, Viñuela E. Production and titration of African swine fever virus in porcine alveolar macrophages. J Virol Methods. 1982;3:303–10.PubMed

38.

Li L, Wu J, Liu D, Du G, Liu Y, Shang Y, Liu X. Transcriptional profiles of murine bone marrow-derived dendritic cells in response to peste des petits ruminants virus. Vet Sci. 2019;6:95.PubMedCentral

39.

Gómez-Puertas P, Oviedo JM, Rodríguez F, Coll J, Escribano JM. Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles. Virology. 1997;228:180–9.PubMed

40.

Neilan JG, Zsak L, Lu Z, Burrage TG, Kutish GF, Rock DL. Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protection. Virology. 2004;319:337–42.PubMed

41.

Teklue T, Sun Y, Abid M, Luo Y, Qiu HJ. Current status and evolving approaches to African swine fever vaccine development. Transbound Emerg Dis. 2020;67:529–42.PubMed

42.

Rau H, Revets H, Cornelis P, Titzmann A, Ruggli N, McCullough KC, Summerfield A. Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. Vaccine. 2006;24:4757–68.PubMed

43.

Leitão A, Malur A, Cartaxeiro C, Vasco G, Cruz B, Cornelis P, Martins CL. Bacterial lipoprotein based expression vectors as tools for the characterisation of African swine fever virus (ASFV) antigens. Arch Virol. 2000;145:1639–57.PubMed

44.

Tarkowski A, Lue C, Moldoveanu Z, Kiyono H, McGhee JR, Mestecky J. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol. 1990;144:3770–8.PubMed

45.

Franke ED, Corradin G, Hoffman SL. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J Immunol. 1997;159:3424–33.PubMed

46.

Wen X, Wen K, Cao D, Li G, Jones RW, Li J, Szu S, Hoshino Y, Yuan L. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines. Vaccine. 2014;32:4420–7.PubMedPubMedCentral

47.

Cui B, Liu X, Zhou P, Fang Y, Zhao D, Zhang Y, Wang Y. Immunogenicity and protective efficacy of recombinant proteins consisting of multiple epitopes of foot-and-mouth disease virus fused with flagellin. Appl Microbiol Biotechnol. 2019;103:3367–79.PubMed

48.

Kumar A, Arora R, Kaur P, Chauhan VS, Sharma P. “Universal” T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. J Immunol. 1992;148:1499–505.PubMed

49.

Basto AP, Morais J, Marcelino E, Leitão A, Santos DM. An efficient depyrogenation method for recombinant bacterial outer membrane lipoproteins. Protein Expr Purif. 2014;98:10–7.PubMed

50.

Volovitz I, Melzer S, Amar S, Bocsi J, Bloch M, Efroni S, Ram Z, Tárnok A. Dendritic cells in the context of human tumors: biology and experimental tools. Int Rev Immunol. 2016;35:116–35.PubMed

51.

Revets H, Pynaert G, Grooten J, De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol. 2005;174:1097–103.PubMed

52.

Basto AP, Badenes M, Almeida SC, Martins C, Duarte A, Santos DM, Leitão A. Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein. Mol Immunol. 2015;64:36–45.PubMed

53.

Onisk DV, Borca MV, Kutish G, Kramer E, Irusta P, Rock DL. Passively transferred African swine fever virus antibodies protect swine against lethal infection. Virology. 1994;198:350–4.PubMed

54.

Escribano JM, Galindo I, Alonso C. Antibody-mediated neutralization of African swine fever virus: myths and facts. Virus Res. 2013;173:101–9.PubMed

55.

Zakaryan H, Revilla Y. African swine fever virus: current state and future perspectives in vaccine and antiviral research. Vet Microbiol. 2016;185:15–9.PubMed

56.

Gartner T, Baeten M, Otieno S, Revets H, De Baetselier P, Huygen K. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. Immunol Lett. 2007;111:26–35.PubMed

57.

Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A. 2005;102:7239–44.PubMedPubMedCentral

58.

Pérez-Núñez D, Sunwoo SY, Sánchez EG, Haley N, García-Belmonte R, Nogal M, Morozov I, Madden D, Gaudreault NN, Mur L, et al. Evaluation of a viral DNA-protein immunization strategy against African swine fever in domestic pigs. Vet Immunol Immunopathol. 2019;208:34–43.PubMed

59.

Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61–8.PubMed

60.

Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, et al. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J Exp Med. 2018;215:1589–608.PubMedPubMedCentral

61.

Zsak L, Onisk DV, Afonso CL, Rock DL. Virulent African swine fever virus isolates are neutralized by swine immune serum and by monoclonal antibodies recognizing a 72-kDa viral protein. Virology. 1993;196:596–602.PubMed

62.

Ruiz Gonzalvo F, Caballero C, Martinez J, Carnero ME. Neutralization of African swine fever virus by sera from African swine fever-resistant pigs. Am J Vet Res. 1986;47:1858–62.PubMed

63.

Jancovich JK, Chapman D, Hansen DT, Robida MD, Loskutov A, Craciunescu F, Borovkov A, Kibler K, Goatley L, King K, et al. Immunization of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins. J Virol. 2018. https://doi.org/10.1128/JVI.02219-17.CrossRefPubMedPubMedCentral

64.

Lopera-Madrid J, Osorio JE, He Y, Xiang Z, Adams LG, Laughlin RC, Mwangi W, Subramanya S, Neilan J, Brake D, et al. Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine. Vet Immunol Immunopathol. 2017;185:20–33.PubMedPubMedCentral

65.

Murgia MV, Mogler M, Certoma A, Green D, Monaghan P, Williams DT, Rowland RRR, Gaudreault NN. Evaluation of an African swine fever (ASF) vaccine strategy incorporating priming with an alphavirus-expressed antigen followed by boosting with attenuated ASF virus. Arch Virol. 2019;164:359–70.PubMed

Title: Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant African swine fever virus proteins fused with bacterial lipoprotein OprI
Publication date: 01-12-2022
Published in: Virology Journal / Issue 1/2022
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-022-01747-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant African swine fever virus proteins fused with bacterial lipoprotein OprI

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Determining host factors contributing to the reactivation of JC virus in kidney transplant recipients

Quantitative proteomic analysis shows involvement of the p38 MAPK pathway in bovine parainfluenza virus type 3 replication

Correction: Virome and nrEVEome diversity of Aedes albopictus mosquitoes from La Reunion Island and China

The underlying mechanism of Guillain-Barré syndrome in a young patient suffered from Japanese encephalitis virus infection: a case report

Establishment and evaluation of a quadruple quantitative real-time PCR assay for simultaneous detection of human coronavirus subtypes

Sensitive and specific serological ELISA for the detection of SARS-CoV-2 infections

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page